NCI Drug Dictionary

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

The NCI Drug Dictionary contains technical definitions and synonyms for drugs/agents used to treat patients with cancer or conditions related to cancer. Each drug entry includes links to check for clinical trials listed in NCI's List of Cancer Clinical Trials.

DNA-dependent protein kinase-targeting siDNA DT01
A proprietary preparation of small interfering DNA (siDNA) molecules with potential chemo/radiosensitizing activity. By mimicking DNA double strand breaks (DSBs), DNA-dependent protein kinase-targeting siDNA DT01 inhibits the non-homologous end joining (NHEJ) process, one of the main DNA repair mechanisms, via binding to and activating DNA-dependent protein kinase (DNA-PK), a core component of the NHEJ complex. DNA-PK activation causes hyper-phosphorylation of histone variant H2AX on DNA and results in a different phosphorylated pattern of H2AX upon ionizing radiation treatment. This ultimately interferes with the repair of DNA DSBs during chemo- or radiotherapy, thereby increasing tumor cell death. The enhanced ability of tumor cells to repair DSBs plays a major role in the resistance of tumor cells to chemo- and radiotherapy. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
Synonym:DNA-PK-targeting siDNA DT01
Code name:DT01